Compare JBGS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | NVAX |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2017 | 1995 |
| Metric | JBGS | NVAX |
|---|---|---|
| Price | $17.63 | $8.03 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 8 |
| Target Price | ★ $18.00 | $9.75 |
| AVG Volume (30 Days) | 541.3K | ★ 4.2M |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | $501,226,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | ★ N/A | $3.87 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $13.28 | $5.01 |
| 52 Week High | $24.30 | $10.65 |
| Indicator | JBGS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 60.99 |
| Support Level | $16.84 | $7.15 |
| Resistance Level | $17.63 | $8.81 |
| Average True Range (ATR) | 0.41 | 0.41 |
| MACD | 0.12 | 0.11 |
| Stochastic Oscillator | 98.21 | 64.99 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.